Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI200243 |
Pages: 110 |
Jan 2020 |
The Global Intrathecal Drug Delivery System Market was $ 975.1 Million in 2019 and forecast will be $ 1,662.0 Million in 2027, registering a CAGR of 7.2% from 2019 to 2027.
Intrathecal Drug Delivery plays the crucial role in the treatment of intractable pain in a small group of suitably selected patients, such as significant reduction in quality of life along with that have no other treatment. Intrathecal drug delivery, also called as the "pain pump," which uses the small pump for the delivery of pain medication directly to patient’s spinal cord.
Intrathecal drug delivery system market drivers such as increasing demand for (IDD) Intrathecal Drug Delivery system along with extensively improved analgesia are anticipated to upsurge the global market of intrathecal drug delivery system. Unavoidable cancer pain treated with dosages of opioids may cause systematic complications such as excessive sedation and pneumonia. On the other hand, intrathecal drug delivery system has less adverse effects as compare to traditional opioid-based (morphine & morphine - like) treatments. Therefore, it is expected that intrathecal drug delivery system may boost the market in upcoming years.
Complications of ITDD System such as pharmacological complications, mechanical system complications, surgical complications, patient-specific complications are projected to decline the Intrathecal Drug Delivery System market share. Such complications may occur during the pump refill related to either reprogramming error, or medication error leading to systemic toxicity or death.
Adoption of IT therapies for cancer cases coupled with numerous prospective trials over terminal illness and cancer are expected to create enormous opportunities for the growth of intrathecal drug delivery system market. For instance, IT therapy has become widely accepted alternative for the standard medical management for patients of cancer. These therapies can effectively decrease neuropathic pain of cancer patient, along with decreasing the requirement for supplementary opioids. For instance, as per Staats et al study, it is found that AIDS patient suffering from pain experienced statistically and clinically significant analgesia when treated with implantable device.
Source: Research Dive Analysis
Externalized and connected to a pump market generated a revenue of $801.9 million in 2019, and is further projected to reach up to $1,358.6 million by the year of 2027.
Depending on product type the market is divided into externalized and connected to a pump and Fully Implemented. Externalized and connected to a pump has the highest market share owing to Rising demand for Intrathecal Drug Delivery System for cancer pain and cost–effectiveness cancer pain treatment.
Source: Research Dive Analysis
Spasticity Management segment generated a revenue of $668.0 million in 2019, and is further projected to reach upto $1,140.2 million by the year of 2027.
By Application, Intrathecal Drug Delivery System market is categorized into Pain Management and Spasticity Management. Spasticity Management contributes the most among the application segment. With the advent of fully programmable systems spasticity is managed by controlling the flow of drug delivery which is essential as spasticity patients require varying drug based on condition and body requirement.
North America has the highest intrathecal drug delivery system market size globally and is expected generate revenue of $392.7 million in 2019, and is further projected to reach upto $695.9 million by the year of 2027.
In North America the growth of fully implanted Intrathecal drug device is on the rise due to ease of usage which signifies better control and long-lasting nature of the Intrathecal devices. Thus, this is one of the major driving factors for Intrathecal drug devices. Spasticity management is also one of the major reasons why an ITDD system is growing in North America.
U.S, hold the majority of the share of the North America market and it is one of the leading countries globally. Companies are spending heavily on research & Development activities, inorder to provide innovative and effective pain management solution thereby driving the growth of Intrathecal Drug delivery systems in the country. For instance, In U.S, the FDA approved the SynchroMed II myPTM Personal Therapy Manager of Medtronic Company. This has significant usage for patients suffering from chronic pain.
Source: Research Dive Analysis
Some of the prominent manufacturers of Intrathecal drug delivery system include Medtronic Plc, Flownix Medical Inc, Teleflex Incorporated, DePay Synthes, Tricumed Medizintechnik GmbH, Smiths Group Plc, Summit Medical Group, B Braun Melsungen AG, Becton, Dickinson & Company and Fresenius Medical Care AG & Co. KGaA. To gain competitive advantage these companies investing heavily in R&D for devolving fully programmable ITDD which can be fully implanted within the body and is safe for use coupled with the ability to control the flow of the drug delivery.
Aspect | Particulars |
Historical Market Estimations | 2018-2019 |
Base Year for Market Estimation | 2018 |
Forecast timeline for Market Projection | 2020-2027 |
Geographical Scope | North America, Europe, Asia-Pacific, LAMEA |
By Product Type |
|
Segmentation by application |
|
Key Countries covered | U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia |
Key Companies Profiled |
|
Source: Research Dive Analysis
1. Research Methodology
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.4.1. Assumptions
1.4.2. Forecast parameters
1.5. Data sources
1.5.1. Primary
1.5.2. Secondary
2. Executive Summary
2.1. 360° summary
2.2. Product Type
2.3. Application
3. Market overview
3.1. Market segmentation & definitions
3.2. Key takeaways
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Technology landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Market value chain analysis
3.8.1. Stress point analysis
3.9. Strategic overview
4. Intrathecal Drug Delivery Systems Market, by Product
4.1. Externalized and connected to a pump
4.1.1. Market size and forecast, by region, 2016-2026
4.1.2. Comparative market share analysis, 2018 & 2026
4.2. Fully Implanted
4.2.1. Market size and forecast, by region, 2016-2026
4.2.2. Comparative market share analysis, 2018 & 2026
5. Intrathecal Drug Delivery Systems Market, by Application
5.1. Pain Management
5.1.1. Market size and forecast, by region, 2016-2026
5.1.2. Comparative market share analysis, 2018 & 2026
5.2. Spasticity Management
5.2.1. Market size and forecast, by region, 2016-2026
5.2.2. Comparative market share analysis, 2018 & 2026
6. Intrathecal Drug Delivery Systems Market, by Region
6.1. North America
6.1.1. Market size and forecast, by Product, 2016-2026
6.1.2. Market size and forecast, by application, 2016-2026
6.1.3. Market size and forecast, by country, 2016-2026
6.1.4. Comparative market share analysis, 2018 & 2026
6.1.5. U.S.
6.1.5.1. Market size and forecast, by Product, 2016-2026
6.1.5.2. Market size and forecast, by application, 2016-2026
6.1.5.3. Comparative market share analysis, 2018 & 2026
6.1.6. Canada
6.1.6.1. Market size and forecast, by Product, 2016-2026
6.1.6.2. Market size and forecast, by application, 2016-2026
6.1.6.3. Comparative market share analysis, 2018 & 2026
6.1.7. Mexico
6.1.7.1. Market size and forecast, by Product, 2016-2026
6.1.7.2. Market size and forecast, by application, 2016-2026
6.1.7.3. Comparative market share analysis, 2018 & 2026
6.2. Europe
6.2.1. Market size and forecast, by Product, 2016-2026
6.2.2. Market size and forecast, by application, 2016-2026
6.2.3. Market size and forecast, by country, 2016-2026
6.2.4. Comparative market share analysis, 2018 & 2026
6.2.5. Germany
6.2.5.1. Market size and forecast, by Product, 2016-2026
6.2.5.2. Market size and forecast, by application, 2016-2026
6.2.5.3. Comparative market share analysis, 2018 & 2026
6.2.6. Spain
6.2.6.1. Market size and forecast, by Product, 2016-2026
6.2.6.2. Market size and forecast, by application, 2016-2026
6.2.6.3. Comparative market share analysis, 2018 & 2026
6.2.7. France
6.2.7.1. Market size and forecast, by Product, 2016-2026
6.2.7.2. Market size and forecast, by application, 2016-2026
6.2.7.3. Comparative market share analysis, 2018 & 2026
6.2.8. Italy
6.2.8.1. Market size and forecast, by Product, 2016-2026
6.2.8.2. Market size and forecast, by application, 2016-2026
6.2.8.3. Comparative market share analysis, 2018 & 2026
6.2.9. Rest of the Europe
6.2.9.1. Market size and forecast, by Product, 2016-2026
6.2.9.2. Market size and forecast, by application, 2016-2026
6.2.9.3. Comparative market share analysis, 2018 & 2026
6.3. Asia-Pacific
6.3.1. Market size and forecast, by Product, 2016-2026
6.3.2. Market size and forecast, by application, 2016-2026
6.3.3. Market size and forecast, by country, 2016-2026
6.3.4. Comparative market share analysis, 2018 & 2026
6.3.5. China
6.3.5.1. Market size and forecast, by Product, 2016-2026
6.3.5.2. Market size and forecast, by application, 2016-2026
6.3.5.3. Comparative market share analysis, 2018 & 2026
6.3.6. Japan
6.3.6.1. Market size and forecast, by Product, 2016-2026
6.3.6.2. Market size and forecast, by application, 2016-2026
6.3.6.3. Comparative market share analysis, 2018 & 2026
6.3.7. India
6.3.7.1. Market size and forecast, by Product, 2016-2026
6.3.7.2. Market size and forecast, by application, 2016-2026
6.3.7.3. Comparative market share analysis, 2018 & 2026
6.3.8. Australia
6.3.8.1. Market size and forecast, by Product, 2016-2026
6.3.8.2. Market size and forecast, by application, 2016-2026
6.3.8.3. Comparative market share analysis, 2018 & 2026
6.3.9. South Korea
6.3.9.1. Market size and forecast, by Product, 2016-2026
6.3.9.2. Market size and forecast, by application, 2016-2026
6.3.9.3. Comparative market share analysis, 2018 & 2026
6.3.10. Rest of the Asia Pacific
6.3.10.1. Market size and forecast, by Product, 2016-2026
6.3.10.2. Market size and forecast, by application, 2016-2026
6.3.10.3. Comparative market share analysis, 2018 & 2026
6.4. LAMEA
6.4.1. Market size and forecast, by Product, 2016-2026
6.4.2. Market size and forecast, by application, 2016-2026
6.4.3. Market size and forecast, by country, 2016-2026
6.4.4. Comparative market share analysis, 2018 & 2026
6.4.5. Brazil
6.4.5.1. Market size and forecast, by Product, 2016-2026
6.4.5.2. Market size and forecast, by application, 2016-2026
6.4.5.3. Comparative market share analysis, 2018 & 2026
6.4.6. Saudi Arabia
6.4.6.1. Market size and forecast, by Product, 2016-2026
6.4.6.2. Market size and forecast, by application, 2016-2026
6.4.6.3. Comparative market share analysis, 2018 & 2026
6.4.7. South Africa
6.4.7.1. Market size and forecast, by Product, 2016-2026
6.4.7.2. Market size and forecast, by application, 2016-2026
6.4.7.3. Comparative market share analysis, 2018 & 2026
6.4.8. Rest of LAMEA
6.4.8.1. Market size and forecast, by Product, 2016-2026
6.4.8.2. Market size and forecast, by application, 2016-2026
6.4.8.3. Comparative market share analysis, 2018 & 2026
7. Company profiles
7.1. Flownix Medical Inc
7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Product portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis
7.2. Teleflex Incorporated
7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Product portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis
7.3. Medtronics Plc
7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Product portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis
7.4. DePay Synthes
7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Product portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis
7.5. Tricumed Medizintechnik GmbH
7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Product portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis
7.6. Smiths Group Plc
7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Product portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis
7.7. Summit Medical Group.
7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Product portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis
7.8. B Braun Melsungen AG,
7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Product portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization